Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Personalized Medicine in Otolaryngology: Novel Prognostic Markers
share announcement

Personalized Medicine in Otolaryngology: Novel Prognostic Markers

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: 20 October 2024 | Viewed by 2621

Special Issue Editors

Dr. Faris F. Brkic

E-Mail Website
Guest Editor
Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria
Interests: otology; bone-conduction implants; prognostic markers in head and neck oncology; basic head and neck oncology research
Prof. Dr. Wolf-Dieter Baumgartner

E-Mail Website
Guest Editor
Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria
Interests: otology; audiology; neurootology; skull base surgery; cochlear implants; bone-conduction implants; middle ear implants

Special Issue Information

Dear Colleagues,

In recent years, the field of otolaryngology has seen massive improvements in terms of novel treatment options, ranging from checkpoint inhibitors for recurrent and/or metastatic head and neck squamous cell carcinoma, biological treatment for patients with nasal polyposis, to novel active bone-conduction hearing implants for patients with sensorineural, conductive, and mixed hearing loss. In order to further facilitate patient-selection and improve outcomes for patients, efforts have to be undertaken to identify easily obtainable prognostic markers.

This Special Issue aims to collate papers that underscore recent findings and perspectives on future developments in terms of personalized treatments for patients with otolaryngological disorders.

Dr. Faris F. Brkic
Prof. Dr. Wolf-Dieter Baumgartner
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • personalized medicine
  • otorhinolaryngology
  • otology
  • head and neck surgery
  • prognostic markers
  • individualized treatment

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 3834 KiB  
Article
Cochlear Implants after Meningitis and Otosclerosis: A Comparison between Cochlear Ossification and Speech Perception Tests
by Pauliana Lamounier, Natalia Carasek, Valeria Barcelos Daher, Claudiney Cândido Costa, Hugo Valter Lisboa Ramos, Sergio de Castro Martins, Alda Linhares de Freitas Borges, Lucas Alves Teixeira Oliveira and Fayez Bahmad Jr
J. Pers. Med. 2024, 14(4), 428; https://doi.org/10.3390/jpm14040428 - 18 Apr 2024
Viewed by 596
Abstract
(1) Background: Performance after Cochlear Implantation (CI) can vary depending on numerous factors. This study aims to investigate how meningitis or otosclerosis can influence CI performance. (2) Methods: Retrospective analysis of CI performance in patients with etiological diagnosis of meningitis or otosclerosis, comparing [...] Read more.
(1) Background: Performance after Cochlear Implantation (CI) can vary depending on numerous factors. This study aims to investigate how meningitis or otosclerosis can influence CI performance. (2) Methods: Retrospective analysis of CI performance in patients with etiological diagnosis of meningitis or otosclerosis, comparing the etiologies and analyzing the image findings, along with electrode array insertion status and technique. (3) Results: Speech recognition in CI patients with otosclerosis improves faster than in patients with meningitis. Other features such as radiological findings, degree of cochlear ossification, surgical technique used and total or partial insertion of electrodes do not seem to be directly related to speech recognition test performance. (4) Conclusions: Patients should be warned that their postoperative results have a strong correlation with the disease that caused their hearing loss and that, in cases of meningitis, a longer duration of speech–language training may be necessary to reach satisfactory results. Full article
(This article belongs to the Special Issue Personalized Medicine in Otolaryngology: Novel Prognostic Markers)
►▼ Show Figures

Figure 1

11 pages, 599 KiB  
Article
Real-Life Study of Patient Preference for Dupilumab or Revision Surgery for Recurrent Chronic Rhinosinusitis with Nasal Polyps
by Katharina Gangl, David Tianxiang Liu, Tina Bartosik, Nicholas James Campion, Erich Vyskocil, Christian Albert Mueller, Birgit Knerer, Julia Eckl-Dorna and Sven Schneider
J. Pers. Med. 2024, 14(4), 338; https://doi.org/10.3390/jpm14040338 - 23 Mar 2024
Viewed by 774
Abstract
(1) Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) has a high rate of recurrence in patients, despite therapy with local corticosteroids and functional endoscopic sinus surgery. Dupilumab, a recombinant monoclonal human IgG4 antibody directed against the IL-4 receptor α that inhibits both IL-4 [...] Read more.
(1) Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) has a high rate of recurrence in patients, despite therapy with local corticosteroids and functional endoscopic sinus surgery. Dupilumab, a recombinant monoclonal human IgG4 antibody directed against the IL-4 receptor α that inhibits both IL-4 and IL-13 signal transduction, is available for symptomatic therapy. Patient preference between repeated surgery and injection therapy with Dupilumab is not known. (2) Methods: Patients who had experienced at least one surgical intervention for nasal polyps and were treated with Dupilumab for at least 3 months completed a retrospective patient questionnaire. (3) Results: In a cohort of 75 previously operated CRSwNP patients, 91.5% preferred therapy with Dupilumab to repeated surgery for nasal polyps. Preference for Dupilumab in the subgroups of patients with concomitant Non-steroidal Anti-inflammatory Drugs Exacerbated Respiratory Disease (N-ERD) (n = 32), patients with concomitant asthma (n = 25), and patients without concomitant disease (n = 18) was 100%, 96%, and 72%, respectively. (4) Conclusions: Patient preference for Dupilumab over repeat surgery is strongest in previously operated CRSwNP patients with concomitant asthma or N-ERD, but remains very high in patients without concomitant disease. Full article
(This article belongs to the Special Issue Personalized Medicine in Otolaryngology: Novel Prognostic Markers)
►▼ Show Figures

Figure 1

12 pages, 1466 KiB  
Article
Lymphocyte-to-Monocyte Ratio Might Serve as a Prognostic Marker in Young Patients with Tongue Squamous Cell Carcinoma
by Sam Augustine Kandathil, Ina Peter Truta, Lorenz Kadletz-Wanke, Gregor Heiduschka, Stefan Stoiber, Lukas Kenner, Harald Herrmann, Harun Huskic and Faris F. Brkic
J. Pers. Med. 2024, 14(2), 159; https://doi.org/10.3390/jpm14020159 - 30 Jan 2024
Viewed by 950
Abstract
Background: Young patients with tongue squamous cell carcinoma (TSCC) mostly lack typical prognostic markers and face a dire prognosis. The aim of this study was to analyze the prognostic relevance of lymphocyte-to-monocyte ratio (LMR) in TSCC patients, with a special emphasis on patients [...] Read more.
Background: Young patients with tongue squamous cell carcinoma (TSCC) mostly lack typical prognostic markers and face a dire prognosis. The aim of this study was to analyze the prognostic relevance of lymphocyte-to-monocyte ratio (LMR) in TSCC patients, with a special emphasis on patients under 45 years. Methods: This retrospective study included all patients primarily treated for TSCC. The prognostic relevance of LMR was investigated in terms of predicting the overallsurvival (OS) and disease-free survival (DFS). Results: A total of 74 patients were included and the young cohort (<45 years) comprised 27 individuals. The mortality and recurrence rates were 39.2% (n = 29) and 37.8% (n = 28), respectively. OS and DFS were significantly shorter in the low LMR group within the whole cohort. Furthermore, low LMR was associated with worse prognosis, particularly inferior OS (median OS 1.7 vs. 14.6 years, p = 0.0156) and worse DFS (median DFS 0.8 years vs. not reached, p = 0.0405) in the young patient cohort. Conclusions: Our results reveal that pretreatment LMR might become a prognostic tool for young TSCC patients, especially due to its availability. However, further studies on larger cohorts are necessary to validate our results. Full article
(This article belongs to the Special Issue Personalized Medicine in Otolaryngology: Novel Prognostic Markers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop